Update on the Pharmacological Treatment of Alzheimer’s Disease

Alzheimer’s disease (AD) is the most common neurodegenerative disorder. Worldwide prevalence of the disease is estimated at more than 24 million cases. With aging of populations, this number will likely increase to more than 80 million cases by the year 2040. The annual incidence worldwide is estimated at 4.6 million cases which is the equivalent of one new case every seven seconds! The pathophysiology of AD is complex and largely misunderstood. It is thought to start with the accumulation of beta-amyloid (Aβ) that leads to deposition of insoluble neuritic or senile plaques. Secondary events in this “amyloid cascade” include hyperphosphorylation of the protein tau into neurofibrillary tangles, inflammation, oxidation, and excitotoxicity that eventually cause activation of apoptotis, cell death and neurotransmitter deficits. This review will briefly summarize recent advances in the pathophysiology of AD and focus on the pharmacological treatment of the cognitive and functional symptoms of AD. It will discuss the roles of vascular prevention, cholinesterase inhibitors and an NMDA-antagonist in the management of AD. It will address the issues thought to be related to the lack of persistence or discontinuation of therapy with cholinesterase inhibitors shown in recent studies and some of the solutions proposed. These include setting realistic expectations in light of a neurodegenerative condition and available symptomatic treatments, slowly titrating medications, and using alternate routes of administration. Finally, it will introduce future therapeutic options currently under study.

[1]  Kenneth S. Kosik,et al.  The E280A presenilin 1 Alzheimer mutation produces increased Aβ42 deposition and severe cerebellar pathology , 1996, Nature Medicine.

[2]  Simon Lovestone,et al.  Alzheimer's disease – do tauists and baptists finally shake hands? , 2002, Trends in Neurosciences.

[3]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.

[4]  C. Bulpitt,et al.  Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial , 2008, The Lancet Neurology.

[5]  D. Selkoe Alzheimer's disease: genes, proteins, and therapy. , 2001, Physiological reviews.

[6]  P. S. St George-Hyslop,et al.  Therapeutically effective antibodies against amyloid-beta peptide target amyloid-beta residues 4-10 and inhibit cytotoxicity and fibrillogenesis. , 2002, Nature medicine.

[7]  A. Fleisher,et al.  Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. , 2008, Archives of neurology.

[8]  Mary Sano,et al.  Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study , 2008, The Lancet.

[9]  D. Knopman,et al.  The Clinician Interview‐ Based Impression (CIBI) , 1994, Neurology.

[10]  A D Roses,et al.  Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  K. Henke,et al.  Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease , 2003, Neuron.

[12]  J. Raftery,et al.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial , 2004, The Lancet.

[13]  R J Harvey,et al.  Donepezil for dementia due to Alzheimer's disease. , 2006, The Cochrane database of systematic reviews.

[14]  D. Westaway,et al.  Cyclohexanehexol inhibitors of Aβ aggregation prevent and reverse Alzheimer phenotype in a mouse model , 2006, Nature Medicine.

[15]  R O Weller,et al.  Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. , 2008, Brain : a journal of neurology.

[16]  Johannes Kornhuber,et al.  Therapeutic approaches to Alzheimer's disease. , 2006, Brain : a journal of neurology.

[17]  M. Obrenovich,et al.  Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Alzheimer disease , 2009, Neurotoxicity Research.

[18]  C. Bocti,et al.  Management of dementia with a cerebrovascular component , 2007, Alzheimer's & Dementia.

[19]  G. Wilcock,et al.  The cholinergic hypothesis of Alzheimer’s disease: a review of progress , 1999, Journal of neurology, neurosurgery, and psychiatry.

[20]  D. Selkoe Alzheimer Disease: Mechanistic Understanding Predicts Novel Therapies , 2004, Annals of Internal Medicine.

[21]  M. Mattson,et al.  beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  B. Winblad,et al.  IDEAL , 2007, Neurology.

[23]  S. Lovestone,et al.  Neurofibrillary tangles and tau phosphorylation. , 2001, Biochemical Society symposium.

[24]  D. Butterfield,et al.  Direct evidence of oxidative injury produced by the Alzheimer's β-Amyloid peptide (1–40) in cultured hippocampal neurons , 1995, Experimental Neurology.

[25]  D. Bennett,et al.  LONG-TERM FETAL CELL TRANSPLANT IN HUNTINGTON DISEASE: STAYIN’ ALIVE , 2007, Neurology.

[26]  L. Lue,et al.  Soluble Amyloid β Peptide Concentration as a Predictor of Synaptic Change in Alzheimer’s Disease , 1999 .

[27]  Pierre N Tariot,et al.  Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. , 2004, JAMA.

[28]  J. Orgogozo,et al.  Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease , 2007, Neurology.

[29]  M. Billingsley,et al.  Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. , 1997, The Biochemical journal.

[30]  Canadian study of health and aging: study methods and prevalence of dementia. , 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[31]  S. Hendrix,et al.  Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial , 2008, The Lancet Neurology.

[32]  T. Wisniewski,et al.  Biology of Aβ Amyloid in Alzheimer's Disease , 1997, Neurobiology of Disease.

[33]  F. Boller,et al.  Severe impairment battery. A neuropsychological test for severely demented patients. , 1994, Archives of neurology.

[34]  K. Henke,et al.  Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. , 2003, Neuron.

[35]  Neil B. Minkoff,et al.  Recommendations for best practices in the treatment of Alzheimer's disease in managed care. , 2006, The American journal of geriatric pharmacotherapy.

[36]  A. Mackinnon,et al.  Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. , 2003, Archives of neurology.

[37]  R. Collins,et al.  Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20 536 people with cerebrovascular disease or other high-risk conditions , 2004, The Lancet.

[38]  Serge Gauthier,et al.  Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial , 2002, The Lancet.

[39]  B. Dubois,et al.  Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization , 2003, Neurology.

[40]  E. Aguglia,et al.  Rivastigmine in the treatment of Alzheimer’s disease: an update , 2007, Clinical interventions in aging.

[41]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[42]  L. Thal,et al.  CME Practice parameter : Management of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[43]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[44]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[45]  V. Lee Disruption of the cytoskeleton in Alzheimer's disease , 1995, Current Opinion in Neurobiology.

[46]  D. Westaway,et al.  Therapeutically effective antibodies against amyloid-β peptide target amyloid-β residues 4–10 and inhibit cytotoxicity and fibrillogenesis , 2002, Nature Medicine.

[47]  J. Becker,et al.  Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[48]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[49]  B. Everitt,et al.  Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular disease , 2009, International journal of geriatric psychiatry.

[50]  D. Geldmacher,et al.  Donepezil Is Associated with Delayed Nursing Home Placement in Patients with Alzheimer's Disease , 2003, Journal of the American Geriatrics Society.

[51]  B. Seltzer,et al.  Donepezil: an update , 2007, Expert opinion on pharmacotherapy.

[52]  James A. Mortimer,et al.  Brain Infarction and the Clinical Expression of Alzheimer Disease-Reply , 1997 .

[53]  D. Royall,et al.  Alzheimer disease as a vascular disorder: nosological evidence. , 2002, Stroke.

[54]  J. Tuomilehto,et al.  Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial , 1998, The Lancet.

[55]  J. Schneider,et al.  Neurofibrillary tangles mediate the association of amyloid load with clinical Alzheimer disease and level of cognitive function. , 2004, Archives of neurology.

[56]  V. Lingala,et al.  TREATMENT PERSISTENCY WITH RIVASTIGMINE AND DONEPEZIL IN A LARGE STATE MEDICAID PROGRAM , 2005, Journal of the American Geriatrics Society.

[57]  Robert A. Dean,et al.  Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease , 2006, Neurology.

[58]  M. Dorais,et al.  Drug Utilization Review of Cholinesterase Inhibitors in Quebec , 2008, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[59]  P. Tariot,et al.  Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. , 2006, Neurology.

[60]  H. Chertkow Diagnosis and treatment of dementia: Introduction. Introducing a series based on the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia , 2007, Canadian Medical Association Journal.

[61]  Stefan J. Teipel,et al.  Decreased Activation Along the Dorsal Visual Pathway After a 3-Month Treatment With Galantamine in Mild Alzheimer Disease: A Functional Magnetic Resonance Imaging Study , 2009, Journal of clinical psychopharmacology.

[62]  A. Wall,et al.  PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD , 2008, Neurobiology of Aging.

[63]  K. Rockwood,et al.  Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[64]  J. O'Brien,et al.  Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology , 2006, Journal of psychopharmacology.

[65]  P. Raina,et al.  Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline , 2008, Annals of Internal Medicine.

[66]  R. Hansen,et al.  Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis , 2008, Clinical interventions in aging.

[67]  S. Wisniewski,et al.  Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[68]  C. Masters,et al.  Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.

[69]  Neil Chapman,et al.  Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. , 2003, Archives of internal medicine.

[70]  Khadija Iqbal,et al.  Mechanisms of neurofibrillary degeneration and the formation of neurofibrillary tangles. , 1998, Journal of neural transmission. Supplementum.

[71]  S. M. Sumi,et al.  Amyloid β protein (Aβ) deposition in chromosome 14–linked Alzheimer's disease: Predominance of Aβ42(43) , 1996 .

[72]  J. C. Torre,et al.  Pathophysiology of Neuronal Energy Crisis in Alzheimer’s Disease , 2008, Neurodegenerative Diseases.

[73]  N. Herrmann,et al.  Persistence with Cholinesterase Inhibitor Therapy for Dementia , 2009, Drugs & aging.

[74]  T. Wisniewski,et al.  Biology of A beta amyloid in Alzheimer's disease. , 1997, Neurobiology of disease.

[75]  J. C. Torre,et al.  Alzheimer Disease as a Vascular Disorder: Nosological Evidence , 2002 .

[76]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[77]  Li-sheng Liu,et al.  Treatment of hypertension in patients 80 years of age or older. , 2008, The New England journal of medicine.

[78]  S. Gauthier,et al.  Alzheimer disease , 1981, Neurology.

[79]  C. Geula,et al.  Neurobiology of butyrylcholinesterase , 2003, Nature Reviews Neuroscience.

[80]  N. Bohnen,et al.  Degree of inhibition of cortical acetylcholinesterase activity and cognitive effects by donepezil treatment in Alzheimer’s disease , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[81]  L. Mucke,et al.  Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model , 2007, Science.

[82]  J. Trojanowski,et al.  Phosphorylation of paired helical filament tau in Alzheimer's disease neurofibrillary lesions: focusing on phosphatases , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[83]  B. Oken Practice parameter: Management of dementia (an evidence-based review) , 2001, Neurology.

[84]  S. M. Sumi,et al.  Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43). , 1996, Annals of neurology.

[85]  R DeJong,et al.  Measurement of quality-of-life changes in patients with Alzheimer's disease. , 1989, Clinical therapeutics.

[86]  Olga Pletnikova,et al.  Effect of infarcts on dementia in the Baltimore longitudinal study of aging , 2008, Annals of neurology.

[87]  C. Haass,et al.  Amyloid at the cutting edge: activation of alpha-secretase prevents amyloidogenesis in an Alzheimer disease mouse model. , 2004, The Journal of clinical investigation.

[88]  Hendrik van den Bussche,et al.  Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials , 2005, BMJ : British Medical Journal.

[89]  L. Lue,et al.  Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. , 1999, The American journal of pathology.

[90]  T. Wisniewski,et al.  Amyloid-β immunisation for Alzheimer's disease , 2008, The Lancet Neurology.

[91]  L. Candelise,et al.  Galantamine for Alzheimer’s Disease and Mild Cognitive Impairment , 2007, Neuroepidemiology.

[92]  D. Selkoe Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[93]  D. Iarussi,et al.  Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. , 1999, American journal of hypertension.

[94]  H. Kavirajan Memantine: a comprehensive review of safety and efficacy. , 2009, Expert opinion on drug safety.

[95]  C. Patterson,et al.  Comparison studies of cholinesterase inhibitors for Alzheimer's disease , 2004, The Lancet Neurology.

[96]  Nathan Herrmann,et al.  Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[97]  P. Macfarlane,et al.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial , 2002, The Lancet.

[98]  S H Ferris,et al.  Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. , 1997, Alzheimer disease and associated disorders.

[99]  J. C. de la Torre,et al.  For Personal Use. Only Reproduce with Permission the Lancet Publishing Group. Personal View Is Ad Neurodegenerative or Vascular? Is Ad Neurodegenerative? Is Alzheimer's Disease a Neurodegenerative or a Vascular Disorder? Data, Dogma, and Dialectics , 2022 .

[100]  T. Golde Disease modifying therapy for AD? 1 , 2006, Journal of neurochemistry.

[101]  A. Delacourte,et al.  The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer’s disease , 1999, Neurology.

[102]  J. Coyle,et al.  Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. , 1982, Science.

[103]  Howard Fillit,et al.  Economics of dementia and pharmacoeconomics of dementia therapy. , 2005, The American journal of geriatric pharmacotherapy.

[104]  Ian G. McKeith,et al.  Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales , 2001, The Lancet.

[105]  J Driver,et al.  Modulation of fusiform cortex activity by cholinesterase inhibition predicts effects on subsequent memory. , 2009, Brain : a journal of neurology.

[106]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[107]  C. Pedone,et al.  Antipsychotics for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD) , 2008, Current neuropharmacology.

[108]  W. Noble,et al.  Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[109]  I. Deary,et al.  The Effects of Antihypertensive Treatment on Cognitive Function: Results from the HOPE Study , 1996, Journal of the American Geriatrics Society.

[110]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[111]  Carol Brayne,et al.  Age, neuropathology, and dementia. , 2009, The New England journal of medicine.

[112]  G C Roman,et al.  Brain infarction and the clinical expression of Alzheimer disease. , 1997, JAMA.

[113]  W W Offen,et al.  Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. , 1997, Archives of neurology.

[114]  K. Lanctôt,et al.  Management of mild to moderate Alzheimer’s disease and dementia , 2007, Alzheimer's & Dementia.

[115]  Jeffrey L. Cummings,et al.  Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[116]  Alteration in brain presenilin 1 mRNA expression in early onset familial Alzheimer's disease. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[117]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[118]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[119]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[120]  D. Suh,et al.  Drug Persistency of Two Cholinesterase Inhibitors , 2005, Drugs & aging.

[121]  S. Arnold,et al.  Cool with plaques and tangles. , 2009, The New England journal of medicine.

[122]  L. Thal,et al.  Choline chloride fails to improve cognition in Alzheimer's disease , 1981, Neurobiology of Aging.

[123]  Liang Li,et al.  Current experimental therapy for Alzheimer's disease. , 2007, Current neuropharmacology.

[124]  J. C. Torre,et al.  Critically attained threshold of cerebral hypoperfusion: the CATCH hypothesis of Alzheimer’s pathogenesis , 2000, Neurobiology of Aging.

[125]  D. Leys,et al.  Treatment of vascular risk factors is associated with slower decline in Alzheimer disease , 2009, Neurology.

[126]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.

[127]  Chi Li,et al.  Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[128]  C. Lyketsos,et al.  Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease. , 2006, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[129]  H. Hanyu,et al.  SPECT Follow‐Up Study of Cerebral Blood Flow Changes During Donepezil Therapy in Patients with Alzheimer's Disease , 2006, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[130]  M. Sano,et al.  An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimer's Disease , 1997, Alzheimer disease and associated disorders.

[131]  K. Ashe A tale about tau. , 2007, The New England journal of medicine.

[132]  D. Dickson,et al.  The Pathogenesis of Senile Plaques , 1997, Journal of neuropathology and experimental neurology.

[133]  H. Fillit,et al.  The Economic Benefits of Acetylcholinesterase Inhibitors for Patients with Alzheimer Disease and Associated Dementias , 2004, Alzheimer disease and associated disorders.

[134]  H. Braak,et al.  Demonstration of Amyloid Deposits and Neurofibrillary Changes in Whole Brain Sections , 1991, Brain pathology.

[135]  F. Sherriff,et al.  Memantine for dementia. , 2005, The Cochrane database of systematic reviews.

[136]  A. Nordberg,et al.  Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months , 2002, Neurology.

[137]  Xiuzhen Zhang,et al.  Valproic acid as a promising agent to combat Alzheimer's disease , 2010, Brain Research Bulletin.

[138]  S. Lipton,et al.  NMDA receptors: from genes to channels. , 1996, Trends in pharmacological sciences.